CG
ACET icon

Carlyle Group’s Adicet Bio ACET Stock Holding History

Carlyle Group’s Portfolio ACET Stock Details ACET Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.26M Hold
184,295
– – 0.01% 11
2025
Q4 		$1.54M Hold
184,295
– – 0.01% 12
2025
Q3 		$2.39M Hold
184,295
– – 0.06% 10
2025
Q2 		$1.8M Hold
184,295
– – 0.04% 14
2025
Q1 		$2.28M Hold
184,295
– – 0.06% 16
2024
Q4 		$2.84M Hold
184,295
– – 0.07% 18
2024
Q3 		$4.25M Hold
184,295
– – 0.45% 13
2024
Q2 		$3.6M Hold
184,295
– – 0.34% 18
2024
Q1 		$6.9M Buy
184,295
+52,083
+39% +$2.15M 0.44% 15
2023
Q4 		$3.98M Hold
132,212
– – 0.19% 18
2023
Q3 		$2.88M Hold
132,212
– – 0.12% 20
2023
Q2 		$5.12M Hold
132,212
– – 0.18% 17
2023
Q1 		$12.2M Buy
+132,212
New +$16.6M 0.36% 15

Other funds holding ACET

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

Carlyle Group's ACET Position: Q1 2026 in Review

Carlyle Group held its Adicet Bio (ACET) position steady in Q1 2026 at 184,295 shares worth $1.26M. The position accounts for 0.01% of the portfolio, ranked #11.

Carlyle Group first reported a position in ACET in Q1 2023 and has held it in 13 quarters since. The position peaked at $12.2M in Q1 2023. 49 funds tracked by Wall St. Rank hold ACET as of Q1 2026.

  • Carlyle Group held 184,295 shares of Adicet Bio worth $1.26M as of Q1 2026.
  • Carlyle Group left its Adicet Bio share count unchanged in Q1 2026.
  • Adicet Bio made up 0.01% of Carlyle Group's portfolio in Q1 2026, its #11 holding.
  • Carlyle Group first reported a position in Adicet Bio in Q1 2023 and has held it in 13 quarters since.
  • Carlyle Group's Adicet Bio position peaked at $12.2M in Q1 2023.
  • 49 funds tracked by Wall St. Rank held Adicet Bio as of Q1 2026.

Based on Carlyle Group's 13F filing for Q1 2026, filed 8 May 2026.